Skip to main content

Sex differences in ischemic heart disease and heart failure biomarkers


Since 1984, each year, more women than men die of ischemic heart disease (IHD) and heart failure (HF), yet more men are diagnosed. Because biomarker assessment is often the first diagnostic employed in such patients, understanding biomarker differences in men vs. women may improve female morbidity and mortality rates.

Some key examples of cardiac biomarker utility based on sex include contemporary use of “unisex” troponin reference intervals under-diagnosing myocardial necrosis in women; greater use of hsCRP in the setting of acute coronary syndrome (ACS) could lead to better stratification in women; and greater use of BNP with sex-specific thresholds in ACS could also lead to more timely risk stratification in women.

Accurate diagnosis, appropriate risk management, and monitoring are key in the prevention and treatment of cardiovascular diseases; however, the assessment tools used must also be useful or at least assessed for utility in both sexes. In other words, going forward, we need to evaluate sex-specific reference intervals or cutoffs for laboratory tests used to assess cardiovascular disease to help close the diagnostic gap between men and women.


Since 1984, each year, more women than men die of cardiovascular disease (CVD) [1], yet more men than women are diagnosed [2]. While overall female CVD death rates began to decline in the 2000s [3], there continues to be both an excess of female deaths and many remaining unknowns as to the etiology of sex-based differences. Ischemic heart disease (IHD) is the leading cause of death for women in the USA, killing 289,758 women in 2013—which equates to approximately 1 in every 4 female deaths [4]. Heart failure with preserved ejection fraction (HFpEF) is a condition which predominantly impacts women, is currently poorly understood, and lacks evidence-based therapy [5]. The aging of the baby boomer population combined with female longevity is a convenient but inaccurate explanation for these sex differences, because CVD death rates have actually declined in older women concomitant with the declines for both older and younger men, compared to an increase in younger women [6]. Recent work suggests that there may be a diagnosis gap, whereby relatively more men are diagnosed and treated for IHD and HF compared to women, potentially accounting in part for increased female mortality [7].

Prior work suggests that under-diagnosis of IHD in women could be due to sex differences in phenotypic presentation, i.e., the signs and symptoms of IHD in men vs. women [8]. IHD and HF are diagnosed by a combination of (1) clinical presentation, (2) circulating biomarker levels, and (3) imaging. IHD symptoms appear to differ between women and men and also by ethnicity, which can contribute to a failure to proceed with appropriate diagnostic tests and procedures. Specifically, women with acute coronary syndrome (ACS) more often present with atypical symptoms such as jaw pain and nausea compared with men [9], and non-Caucasian ethnicities are associated with higher rates of atypical angina symptoms more often ascribed to digestive rather than cardiac etiology [10]. Because biomarker assessment is a more specific and often the first diagnostic measure employed in patients with suspected CVD, understanding cardiac biomarker differences in men vs. women may improve female CVD morbidity and mortality rates.

In 2001, a National Institutes of Health (NIH) working group standardized the definition of a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” and also defined types of biomarkers based on the information they provide [11]. Table 1 provides definitions adapted from the NIH working group document.

Table 1 Biomarkers: a basic glossary (derived from NIH working group) [11]

Several clinically established cardiovascular circulating biomarkers are measured in order to help diagnose, stratify risk, and monitor people with suspected ACS, acute myocardial infarction (MI), and HF [12]. Use of one or more of these biomarkers can help physicians identify an IHD and/or HF condition and initiate appropriate therapy, as well as follow the course of disease.

In 2007, the National Academy of Clinical Biochemistry (NACB) and International Federation of Clinical Chemistry (IFCC) committee recommended that sex-specific reference ranges should be developed and utilized in clinical practice for some cardiac biomarkers [13], yet common laboratory practice for most of these biomarkers still revolves around the use of universal ranges or cutoffs for both men and women. As mentioned earlier, lack of sex-specific cardiac biomarker thresholds in men and women may contribute to IHD and HF under-diagnosis in women and potentially increased morbidity and mortality as a result, or conversely an over-diagnosis in men. Additionally, coronary microvascular dysfunction appears to be more prevalent in women than in men and may result in part from hormonal and immunomodulatory differences in men and women, which further supports a need to define sex-specific measures and thresholds when studying cardiovascular disease [14,15,16].

We review here literature that highlights sex differences in IHD and HF biomarkers and also discuss instances where knowledge of sex differences is lacking and likely warranted.


Table 2 lists cardiac circulating biomarkers, including markers of inflammation and atherosclerosis, endothelial function, thrombosis, oxidative stress, ischemia/necrosis, hemodynamic stress, HF mortality, renal dysfunction, metabolic dysfunction/lipid dysregulation, and brain injury, used in our literature search spanning from the year 2000 to approximately through 2016. We searched the electronic databases of PubMed and MEDLINE via OVID using the aforementioned biomarker categories as keywords with sex or gender differences included. We did not impose any restrictions regarding language, publication date, or study setting. Data and evidence-based statements were extracted from each paper, and relevant references of retrieved articles were used as additional references. The process for these searches is shown in Fig. 1.

Table 2 Cardiac biomarkers (modified with permission) [67]
Fig. 1

Schema of database searches on gender and sex-related biomarkers with search terms specified. Results for PubMed are shown as an example. This search was conducted in 2016

Creatinine kinase MB

At one point in recent history, creatine kinase represented our most cardiac-specific biomarker, especially with development of creatine kinase isoenzyme assays in contrast to previously used (and extremely non-specific) analytes such as lactate dehydrogenase. Creatine kinase (CK) exists as isoenzymes with various combinations of muscle (CKM) and brain (CKB) subunits (i.e., MM, MB, BB). These isoenzymes facilitate the transfer of high-energy phosphates into and out of mitochondria and exist in many tissues including the heart, skeletal muscle, and brain. As a result of vigorous exercise, organ damage, and skeletal muscle disease, they can be nonspecifically elevated in plasma. The MB fraction (or isoenzyme) is most concentrated in the heart tissue, and most clinically applied assays for creatinine kinase MB (CK-MB) measure its mass, which is more sensitive than enzyme activity-based assays. CK-MB represented the “gold standard” for laboratory diagnosis of myocardial infarction (MI) through the late 80s and 90s. Additionally, mass assays for CK-MB mostly avoid picking up macrokinases (i.e., CK isoenzymes bound to IgG or aggregates of mitochondrial CK) that can prevent clear interpretability with activity-based assays. The presence of macrokinases should be considered as a possible cause of elevation when CK-MB is a very high percentage (e.g., > 20%) of total CK [17]. Furthermore, using criteria for CK-MB as fraction of total CK can lead to false elevations due to chronic skeletal muscle disease [18]. CK-MB can account for as much as 50% of total CK elevation with chronic skeletal muscle injury (i.e., dermatomyositis and polymyositis) due to increased production of the B chain of CK protein. An additional area of CK-MB utility is its correlation to infarct size through serial measurements; however, more recent comparisons with cardiac troponins suggest that troponins can still provide more accurate estimates [19, 20].

The criterion most commonly used for the diagnosis of acute MI was two serial elevations above the diagnostic cutoff level or a single result more than twice the upper limit of normal. Although CK-MB is approximately 3–4 times more concentrated in the myocardium, it also exists in the skeletal muscle and false-positive elevations occur in a number of clinical settings, including trauma, heavy exertion, and myopathy.

NACB and IFCC guidelines published in 2007 noted that CK-MB is the preferred alternative biomarker for MI, and many hospitals still use it in conjunction with troponin [13], although current American Heart Association/American College of Cardiology (AHA/ACC) guidelines for both non-ST segment elevation MI (NSTEMI) and ST segment elevation MI (STEMI) from 2014 and 2013, respectively, no longer support use of CK-MB for this application. Skeletal muscle is also composed of small amounts of CK-MB (1–3%) [21]. Since men on average have greater body muscle mass, they would be expected to have a higher concentration of this biomarker. Indeed, a sex difference was consistently demonstrated using seven different assays [Abbott AxSYM, Bayer Centaur, Beckman Access, Dade-Behring Dimension RxL, Vitros ECi, Roche, Tosoh AIA] where an over twofold higher 99th percentile for CK-MB was found for males vs. females [22]. Further investigation assessed two different analytical platforms [UniCel® DxI 800 and Access® 2] to establish sex-specific 99th percentiles for CK-MB mass and found values to be significantly higher in men than in women [23].

These data strongly suggest that much like troponins (as discussed in the next section), use of male CK-MB 99th percentile would be expected to under-diagnose myocardial necrosis in women. Indeed, Wiviott et al. suggest that women with high probability of ACS NSTEMI, but no biomarker elevation, could benefit from a multimarker approach [24].


Cardiac troponins (cTn) are muscle regulatory proteins that control the calcium-mediated interaction of actin and myosin (muscle contraction) and consist of cytosolic and structural pools, with most troponin present as structural proteins [25]. Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are the two protein subunits of the troponin tri protein-complex (troponin C being the third but is not cardiac specific), which are actually measured in plasma to assess cardiac damage. Both cTnI and TnT are independently measured using monoclonal antibodies in immunometric assay formats resulting in clinical assays specific (almost exclusively) to cardiac muscle damage. While they do not specifically identify the underlying cause of cell injury, they are considered to be the current gold-standard biomarker for myocardial injury and necrosis [13].

Cardiac troponin concentrations typically begin to rise 2–3 h after the onset of acute MI. At 2–3 h after initial presentation, up to 80% of patients with MI will have detectable troponin elevations. Markers that rise earlier than troponins, such as myoglobin and CK isoforms, actually have been shown to provide little additional diagnostic or clinical utility when a sufficiently analytically sensitive troponin assay (i.e., an assay with a coefficient of variation approaching 10% at the 99th percentile) is employed in the lab [26], although, in practice, desired precision at the 99th percentile is typically not achieved for existing (contemporary) US Food and Drug Administration (FDA) approved troponin assays that are in use. cTnI is considered specific to the heart muscle as no other isoform of this fraction has even been detected or discovered in other muscle tissue [27]; however, cTnT is believed to be potentially expressed to a very minor extent in the skeletal muscle, due to its previous measurement in patients with specific skeletal muscle myopathies [28]. TnI can also be mildly overexpressed in these rare patients, but the prevalence of elevated expression compared to TnT is much lower. Despite their current widespread use, contemporary cardiac troponin assays lack sex-specific reference value reporting, even for widely used commercial assays that indicate 99th percentile cutoffs or ranges 1.2–2.4-fold higher in males than females [29]. Healthy animal data demonstrates higher circulating cTnI concentrations in males compared to females of the same species [30].

Further investigation has evaluated sex differences in troponin and clinical manifestations of CVD. Säfström et al. evaluated exercise stress testing and cTnT in subjects with suspected myocardial ischemia [31]. The women studied were older and had higher incidence of CVD-related events and diagnoses; however, only 49% of the women compared to 69% of men had cTnT levels that met the threshold for MI (≥ 0.20 μg/l) [31]. Shoaibi and colleagues evaluated women and men diagnosed with AMI using standard biomarker criteria and found no variation in the assay sensitivity and specificity or troponin level by sex [32]; as well as gender, assay performance and sensitivity influenced outcome [33]. Newer “high sensitivity” clinical and preclinical cTnI and cTnT assays that do not demonstrate loss of specificity could be helpful in closing the gender bias. These new high-sensitivity assays will be expected to demonstrate robust precision and sensitivity, e.g., a highly reproducible CV < 10% at the 99th percentile concentration of the reference population, that can also be reproduced in routine practice in the clinical lab. Another important change with high-sensitivity assays will be the reporting units going to nanograms/liter instead of nanograms/milliliter (as currently reported); this is due to the at least threefold increase in sensitivity that is gained with high-sensitivity troponin assays over existing FDA-approved assays. Thus far in Europe, most high-sensitivity assays have been establishing sex-specific reference range criteria.

Overall, these data suggest that at-risk women may be missed when using male sex-specific thresholds and that, as a result, those women who meet standard MI troponin measurement criteria have suffered a greater degree of myocardial damage [33]. Indeed, a recent study demonstrated that standard troponin criteria failed to detect one out of five acute MIs occurring in women, which was, not surprisingly, associated with an elevated death rate [34], while another study demonstrated varying 99th percentiles for hs-cTnI related to lack of a uniform protocol for healthy reference population selection [35].

High-sensitivity C-reactive protein

C-reactive protein (CRP) [10, 36, 37] is a protein synthesized in the liver in response to inflammation. Measurement of high-sensitivity CRP (hsCRP) in serum/plasma via appropriate assay formats can be used as a CVD risk marker in both men and women [38]. The concentration of hsCRP in plasma is on average higher in women (by potentially up to 60%) compared to men with and without CVD risk factors [37], a difference that is demonstrable by adolescence, whereby girls exhibit measurable CRP elevations compared to non-significant change in boys [39, 40], suggesting hormonal modulation.

While there are hundreds of papers discussing the use of hsCRP in diagnosis/prognosis of CVD and related disorders, a selection of recent presentative papers is highlighted here focusing on use in women and men. In the setting of ACS, CRP is a relatively better prognostic predictor for women compared to men [41], yet CRP is not currently used in the acute setting for decision-making for MI, not even as part of a multimarker panel. Although CRP levels were found to be lower in women than in men with HF in a prior report by Meyer et al., the women included in their study had a lesser number of comorbidities compared to the men, which may have been reflected in the lower CRP levels observed [42].

A significant relationship between hsCRP and body mass index (BMI) has been described in healthy women (P = 0.002), while no significant correlation was found in healthy men (P = 0.09) [36]. To understand this, Cartier et al. compared women and men with similar visceral and subcutaneous adiposity, respectively. They found that subcutaneous and not visceral adiposity explained the higher CRP levels in women [42]. Accordingly, given the known sex difference of higher subcutaneous adipose tissue in women compared to men [37] and the link between subcutaneous adipose tissue and CRP levels, it is not surprising to find significant sex differences in hsCRP levels despite matching for age and BMI [37]. Additionally, the finding of higher CRP in diabetic women, in particular with no known CVD, may further support its use in the “at-risk” female population [43]. This finding is further supported by a 2016 study by Garcia et al. which concluded that statistically significantly higher hsCRP levels were observed in women vs. men with metabolic syndrome risk factors, suggesting that hsCRP can be used to help stratify CVD risk even before type 2 diabetes develops [44].

Overall, these data suggest that greater use of CRP determination in the setting of ACS risk could lead to better stratification in women, as also evidenced in prior work [41].

Brain natriuretic peptide

B-type natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) are cardiac hormones secreted by the myocardium in response to excessive stretching of cardiomyocytes and are involved in hemodynamic regulation. BNP is a biologically active 32-amino acid polypeptide which functions to decrease systemic vascular resistance and increase natriuresis in times of excessive cardiac stretch. BNP is the active cleavage product of proBNP (108 aa), which is in turn produced by cleavage of the preprohormone preproBNP (134 aa precursor). BNP has been used as a biomarker for cardiac dysfunction and HF for years [45]. NT-proBNP is the remaining 76-amino acid cleavage product of proBNP and has also been used as a marker of HF even though it is not the physiologically active hormone. The half-lives of the natriuretic peptides are normally in the following order ANP < BNP < NT-proBNP, which is why BNP and NT-proBNP are measured in HF due to their longer half-lives. Additionally, owing to half-life and cleavage differences, the reference intervals for BNP and NT-proBNP are naturally quite different regardless of sex. Studies in healthy and diseased subjects have shown that BNP levels are significantly higher in women compared to men; however, cut points for this sex-based difference have not been conclusively established [24, 46,47,48], and it has also been observed that BNP concentration is correlated to age [49]. When comparing two commercial assays, plasma BNP was found to be 32% higher in women than in men by Shionogi and Co. assay and 80% higher by Biosite assay [48]. In one study, higher BNP levels in both women and men were associated with left ventricular systolic dysfunction; however, BNP was associated with left ventricular end-diastolic diameter/body surface area and atrial fibrillation only in women [46].

Although the etiology of higher circulating BNP levels in women is unknown, sex-specific modifier genes or mechanism might explain the association with female sex and increased BNP in tissue and circulating forms, which are modulated by disease status [50, 51]. Of particular interest in the animal model that recapitulates Takotsubo (Ampulla) cardiomyopathy, a rare stress-induced cardiomyopathy occurs predominantly in postmenopausal women, where the expression of BNP gene (and presumably, the protein product) was upregulated in the myocardium [52, 53]. Redfield et al. have described higher BNP levels in women on hormone replacement therapy compared to women not on therapy, suggesting that BNP production may be sensitive to estrogen regulation [48]. One randomized, controlled trial reported no sex differences in BNP levels; however, researchers used specific enrollment criteria that matched women and men to HF severity, resulting in similar BNP levels [42]. Similar to CRP, BNP is a relatively better prognostic predictor in the setting of ACS for women compared to men [41], yet BNP is not typically used clinically unless HF is suspected. However, continuing with the theme of sex as it relates to the use of BNP in HF (i.e., acute decompensated HF in this case), a 2016 study by Nakada et al. out of Japan observed that while there were no significant sex-specific differences in median plasma levels, high BNP vs. low BNP was correlated to a worse prognosis in men, but not women, highlighting that sex-specific differences in natriuretic peptides as they relate to HF are still not fully understood [54].

Normally, women have higher BNP levels; however, BNP levels rise to a lesser degree in women than in men with HF [55]. Therefore, the interpretation of BNP levels should include association with other biomarkers. For future personalized diagnosis and prognosis in ACS and HF patients, a temporal multimarker approach could be employed to monitor the functions of different biological pathways over time. For example, markers for status of cardiac damage (hs-cTnI), markers for pathophysiological status (CRP and other cytokines), and markers for cardiac dysfunction (BNP) can be monitored over time as a multi-marker panel [56,57,58].

On a more recent note, while both BNP and NT-proBNP have historically been used to assess congestive HF, with greater use of BNP overall, this may change with the introduction of sacubitril/valsartan which is a combination neprilysin inhibitor (i.e., sacubitril) and angiotensin receptor blocker (ARB) (i.e., valsartan). Neprilysin is also known as a neutral endopeptidase (NEP) or membrane metallo-endopeptidase (MME) that cleaves various peptides including natriuretic peptides. Use of this neprilysin inhibitor/ARB combo showed dramatic improvement in patient outcomes with systolic HF compared to angiotensin-converting enzyme inhibitor (ACE-inhibitor) enalapril alone in the PARADIGM-HF study [59]. Sacubitril/valsartan prevents degradation of BNP, and thus, its half-life and circulating concentration dramatically increases in patients on this drug. Because the half-life of BNP is extended, measurement of BNP in the lab in order to prognosticate these patients is questionable at best as the concentration does not decrease as expected. However, NT-proBNP appears to be unaffected by neprilysin inhibition, and therefore, early studies are favoring its use over BNP in the growing population of patients that will likely be moved to sacubitril/valsartan. That said, sex-specific differences in NT-proBNP in patients on sacubitril/valsartan warrant further study to potentially hone appropriate dosing and use of this drug.

Additional biomarkers

There was insufficient literature for review regarding sex differences in the remainder of biomarkers listed in Table 2. While there are many knowledge gaps, Meyer et al. evaluated sex differences in a series of cardiovascular biomarkers in a cohort of women and men with HF (Table 3). This work demonstrated significant sex differences in the majority of studies [42] specifically, 6/8 inflammatory, 3/4 remodeling, and 1/1 atherosclerosis biomarkers were higher in men compared to women, while cardiomyocyte stretch was not significantly different. Combined with the prior literature, these data are consistent with the lower incidence of coronary heart disease and higher incidence of HFpEF observed in women compared to men. Notably, the angiogenesis biomarker, vascular endothelial growth factor (VEGF), was the only biomarker that was elevated in women, which is consistent with a prior angiogenesis clinical trial that was positive only in women, and supportive of the emerging concept that female progenitor cells may act as superior regenerative therapeutics compared to progenitor cells from males [60,61,62]. Recent studies have found that plasma levels of the neurotensin precursor hormone proneurotensin predict the development of cardiovascular disease and are significantly higher in women compared to men [63,64,65].

Table 3 Sex-specific biomarker levels in heart failure (reprinted with permission) [42]K


Use of one or more cardiac biomarkers can help physicians identify IHD and/or HF and initiate appropriate therapy for both women and men. While the focus of cardiac biomarker studies in previous decades primarily focused on men, the number of women with IHD and HF has increased, and women overall now account for the majority of cardiovascular disease-related deaths [6]. Recent work suggests that there may be a diagnosis gap, whereby more men are diagnosed and treated for cardiovascular disease compared to women, potentially contributing to higher female mortality rates [7, 34].

Our review highlights the well-described sex differences in multiple IHD and HF biomarkers clinically used on a daily basis to diagnose and treat women and men [13, 22,23,24, 29,30,31,32,33, 42, 46, 47, 53]. This includes the gold-standard troponins (cTnI and cTnT) and its lesser used and useful alternative, CK-MB, which exhibit 99th percentile thresholds that are significantly lower in women than men, yet male standards are still in widespread use; this disparity is a primary contributing factor in failure to accurately and adequately diagnose ischemia and myocardial infarction in women. Additional biomarkers, hsCRP and BNP, are more often elevated and prognostically more useful in women compared to men, yet they are less often clinically employed for risk stratification.

Mounting evidence indicates that the failure to use sex-specific biomarker strategies may contribute to the CVD diagnosis mortality gap, whereby fewer women are being diagnosed but more are dying from CVD. Accurate diagnosis, appropriate management of risk, and ongoing monitoring are key in the prevention and treatment of CVD [66]. Indeed, diagnostic uncertainty portends therapeutic uncertainty and missed treatment opportunities.

The described sex differences in CVD biomarkers reviewed herein suggest that the diagnosis and management of CVD may be optimally personalized for women and men by the use of sex-specific biomarker thresholds in clinical laboratory reporting. This should assist physician recognition of “female-pattern” CVD and reduce the number of false negatives in at-risk women. Appropriate recognition of CVD based on well-defined biomarker sex thresholds will allow for tailored and timely treatment, which will naturally lead to improved outcomes for both sexes. It is time to acknowledge that CVD presents differently not only symptomatically, but also biochemically, in women and men, and future research should focus on identifying these differences and developing sex-specific diagnostic and prognostic guidelines where appropriate.



Acute coronary syndrome


American Heart Association/American College of Cardiology


Acute myocardial infarction


Atrial natriuretic peptide


Angiotensin receptor blocker


Body mass index


B-type natriuretic peptide


Creatine kinase


Creatine kinase brain


Creatine kinase muscle


C-reactive protein


Cardiac troponins


Cardiac troponin I


Cardiac troponin T


Cardiovascular disease


Heart failure (HF) with preserved ejection fraction


High-sensitivity C-reactive protein


International Federation of Clinical Chemistry


Ischemic heart disease


Myocardial infarction


Membrane metallo-endopeptidase


National Academy of Clinical Biochemistry


Neutral endopeptidase


National Institutes of Health


Non-ST segment MI


N-terminal pro b-type natriuretic peptide


Vascular endothelial growth factor


  1. 1.

    Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital Health Stat 10. 2014;260:1–161.

  2. 2.

    Prevention CoDCa. 2011 Final Mortality Data Release Accessed 4 June 2017.

  3. 3.

    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292.

    Article  PubMed  Google Scholar 

  4. 4.

    Xu J, Murphy SL, Kochanek KD, Bastian BA. Deaths: final data for 2013. Natl Vital Stat Rep. 2016;64:1–119.

    PubMed  Google Scholar 

  5. 5.

    Li J, Becher PM, Blankenberg S, Westermann D. Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life? Cardiol Res Pract. 2013;2013:130724.

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol. 2007;50:2128–32.

    Article  PubMed  Google Scholar 

  7. 7.

    Bairey Merz CN. Sex, death, and the diagnosis gap. Circulation. 2014;130:740–2.

    Article  PubMed  Google Scholar 

  8. 8.

    Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol. 2009;54:1561–75.

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Dey S, Flather MD, Devlin G, Brieger D, Gurfinkel EP, Steg PG, Fitzgerald G, Jackson EA, Eagle KA. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart. 2009;95:20–6.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Eastwood JA, Johnson BD, Rutledge T, Bittner V, Whittaker KS, Krantz DS, Cornell CE, Eteiba W, Handberg E, Vido D, Bairey Merz CN. Anginal symptoms, coronary artery disease, and adverse outcomes in Black and White women: the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study. J Womens Health. 2013;22:724–32.

    Article  Google Scholar 

  11. 11.

    Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95.

  12. 12.

    Nagesh CM, Roy A. Role of biomarkers in risk stratification of acute coronary syndrome. Indian J Med Res. 2010;132:627–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH, Cannon CP, Francis G, Morrow DA, Ravkilde J, Storrow AB, Tang W, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Panteghini M, Tate J. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem. 2007;53:547–51.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Ouyang P, Wenger N, Taylor D, Rich-Edwards J, Steiner M, Shaw L, Berga S, Miller V, Bairey Merz N. Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists. Biol Sex Differ. 2016;7:19.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Cullen LA, Mills NL. The use of sex-specific cutpoints for high-sensitivity cardiac troponin assays. Clin Chem. 2016;63(1):261–63.

    Article  Google Scholar 

  16. 16.

    Gore MO, Seliger SL, deFilippi CR, Nambi V, Christenson RH, Hashim IA, Hoogeveen RC, Ayers CR, Sun W, McGuire DK, Ballantyne CM, de Lemos JA. Age and sex dependent upper reference limits for the high sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014;63:1441–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Adams JE 3rd, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation. 1993;88:750–63.

    CAS  Article  Google Scholar 

  18. 18.

    Wolf PL. Abnormalities in serum enzymes in skeletal muscle diseases. Am J Clin Pathol. 1991;95:293–6.

    CAS  Article  Google Scholar 

  19. 19.

    Licka M, Zimmermann R, Zehelein J, Dengler TJ, Katus HA, Kubler W. Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart. 2002;87:520–4.

    CAS  Article  Google Scholar 

  20. 20.

    Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus HA. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol. 2006;48:2192–4.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Mayo Clinic Cardiology: concise textbook (Mayo Clinic Scientific Press). 4 ed. New York: Oxford University Press; 2012.

  22. 22.

    Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem. 2003;49:1331–6.

    CAS  Article  Google Scholar 

  23. 23.

    Zaninotto M, Mion MM, Novello E, Delprete E, Moretti M, Plebani M. Creatine-kinase MB mass: age and sex-associated reference limits in two different platforms that use the same method. Clin Chim Acta. 2009;401:162–4.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004;109:580–6.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Yap C, Aw T. Clinical use and measurement of cardiac troponin (cTn). Proc Singapore Health. 2012;21:312–7.

    Article  Google Scholar 

  26. 26.

    Eggers KM, Oldgren J, Nordenskjold A, Lindahl B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J. 2004;148:574–81.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Bodor GS, Porterfield D, Voss EM, Smith S, Apple FS. Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem. 1995;41:1710–5.

    CAS  PubMed  Google Scholar 

  28. 28.

    Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger B, Asslaber M, Radl R, Beer M, Polacin M, Mair J, Szolar D, Berghold A, Quasthoff S, Binder JS, Rainer PP. Elevated cardiac troponin T in patients with skeletal myopathies. J Am Coll Cardiol. 2018;71:1540–9.

    CAS  Article  Google Scholar 

  29. 29.

    Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem. 2012;58:1574–81.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Herman E, Knapton A, Rosen E, Zhang J, Estis J, Agee SJ, Lu QA, Todd JA, Lipshultz SE. Baseline serum cardiac troponin I concentrations in Sprague-Dawley, spontaneous hypertensive, Wistar, Wistar-Kyoto, and Fisher rats as determined with an ultrasensitive immunoassay. Toxicol Pathol. 2011;39:653–63.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Safstrom K, Lindahl B, Swahn E. Risk stratification in unstable coronary artery disease--exercise test and troponin T from a gender perspective. FRISC-Study Group. Fragmin during InStability in Coronary artery disease. J Am Coll Cardiol. 2000;35:1791–800.

    CAS  Article  Google Scholar 

  32. 32.

    Shoaibi A, Tavris DR, McNulty S. Gender differences in correlates of troponin assay in diagnosis of myocardial infarction. Transl Res. 2009;154:250–6.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Slagman A, Searle J, Vollert JO, Storchmann H, Buschenfelde DM, von Recum J, Vlasny D, Ale-Abaei A, Koch M, Muller C, Muller R, Somasundaram R, Mockel M. Sex differences of troponin test performance in chest pain patients. Int J Cardiol. 2015;187:246–51.

    Article  PubMed  Google Scholar 

  34. 34.

    Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, Cruikshank A, Reid A, Stoddart M, Strachan F, Walker S, Collinson PO, Apple FS, Gray AJ, Fox KA, Newby DE, Mills NL. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ. 2015;350:g7873.

    Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Krintus M, Kozinski M, Boudry P, Lackner K, Lefevre G, Lennartz L, Lotz J, Manysiak S, Shih J, Skadberg O, Chargui AT, Sypniewska G. Defining normality in a European multinational cohort: critical factors influencing the 99th percentile upper reference limit for high sensitivity cardiac troponin I. Int J Cardiol. 2015;187:256–63.

    Article  PubMed  Google Scholar 

  36. 36.

    Arena R, Arrowood JA, Fei DY, Helm S, Kraft KA. The relationship between C-reactive protein and other cardiovascular risk factors in men and women. J Cardpulm Rehabil. 2006;26:323–7. quiz 328-9

    Article  Google Scholar 

  37. 37.

    Rogowski O, Zeltser D, Shapira I, Burke M, Zakut V, Mardi T, Ben-Assayag E, Serov J, Rozenblat M, Berliner S. Gender difference in C-reactive protein concentrations in individuals with atherothrombotic risk factors and apparently healthy ones. Biomarkers. 2004;9:85–92.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Ridker PM. Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 2003;108:e81–e85. doi:

    Article  Google Scholar 

  39. 39.

    Ford ES, Giles WH, Myers GL, Rifai N, Ridker PM, Mannino DM. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem. 2003;49:1353–7.

    CAS  Article  Google Scholar 

  40. 40.

    Shanahan L, Copeland WE, Worthman CM, Erkanli A, Angold A, Costello EJ. Sex-differentiated changes in C-reactive protein from ages 9 to 21: the contributions of BMI and physical/sexual maturation. Psychoneuroendocrinology. 2013;38:2209–17.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Mega JL, Hochman JS, Scirica BM, Murphy SA, Sloan S, McCabe CH, Merlini P, Morrow DA. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36). Circulation. 2010;121:1809–17.

    Article  PubMed  Google Scholar 

  42. 42.

    Meyer S, van der Meer P, van Deursen VM, Jaarsma T, van Veldhuisen DJ, van der Wal MH, Hillege HL, Voors AA. Neurohormonal and clinical sex differences in heart failure. Eur Heart J. 2013;34:2538–47.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Mehta NN, St Clair C, Farouk S, Braunstein S, Schutta M, Iqbal N, Rader D, Reilly MP, Qasim AN, Budharaju V. Gender differences in the association of C-reactive protein with coronary artery calcium in type-2 diabetes. Clin Endocrinol. 2011;74:44–50.

    CAS  Article  Google Scholar 

  44. 44.

    Garcia VP, Rocha HNM, Sales ARK, Rocha NG, da Nóbrega ACL. Sex differences in high sensitivity C-reactive protein in subjects with risk factors of metabolic syndrome. Arq Bras Cardiol. 2016;106:182–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Cartier A, Cote M, Lemieux I, Perusse L, Tremblay A, Bouchard C, Despres JP. Sex differences in inflammatory markers: what is the contribution of visceral adiposity? Am J Clin Nutr. 2009;89:1307–14.

    CAS  Article  PubMed  Google Scholar 

  46. 46.

    Azevedo A, Bettencourt P, Barros H. Demographic, clinical and echocardiographic determinants of B-type natriuretic peptide plasma concentration. A population-based study. Rev Port Cardiol. 2007;26:105–13.

    PubMed  Google Scholar 

  47. 47.

    Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what’s next? Circulation. 2002;105:2328–31.

    Article  Google Scholar 

  48. 48.

    Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976–82.

    CAS  Article  Google Scholar 

  49. 49.

    Keyzer JM, Hoffmann JJ, Ringoir L, Nabbe KC, Widdershoven JW, Pop VJ. Age- and gender-specific brain natriuretic peptide (BNP) reference ranges in primary care. Clin Chem Lab Med. 2014;52:1341–6.

    CAS  Article  PubMed  Google Scholar 

  50. 50.

    Haroon J, Foureaux G, Martins AS, Ferreira AJ, Reis AM, Javed Q. Gender differences in normal left ventricle of adult FVB/N mice due to variation in interleukins and natriuretic peptides expression levels. Cytokine. 2015;71:54–9.

    CAS  Article  PubMed  Google Scholar 

  51. 51.

    Witt H, Schubert C, Jaekel J, Fliegner D, Penkalla A, Tiemann K, Stypmann J, Roepcke S, Brokat S, Mahmoodzadeh S, Brozova E, Davidson MM, Ruiz Noppinger P, Grohe C, Regitz-Zagrosek V. Sex-specific pathways in early cardiac response to pressure overload in mice. J Mol Med. 2008;86:1013–24.

    Article  PubMed  PubMed Central  Google Scholar 

  52. 52.

    Ueyama T. Emotional stress-induced Tako-tsubo cardiomyopathy: animal model and molecular mechanism. Ann N Y Acad Sci. 2004;1018:437–44.

    CAS  Article  PubMed  Google Scholar 

  53. 53.

    Wong PG, Armstrong DW, Tse MY, Brander EP, Pang SC. Sex-specific differences in natriuretic peptide and nitric oxide synthase expression in ANP gene-disrupted mice. Mol Cell Biochem. 2013;374:125–35.

    CAS  Article  PubMed  Google Scholar 

  54. 54.

    Nakada Y, Kawakami R, Nakano T, Takitsume A, Nakagawa H, Ueda T, Nishida T, Onoue K, Soeda T, Okayama S, Takeda Y, Watanabe M, Kawata H, Okura H, Saito Y. Sex differences in clinical characteristics and long-term outcome in acute decompensated heart failure patients with preserved and reduced ejection fraction. Am J Physiol Heart Circ Physiol. 2016;310:H813–20.

    Article  PubMed  Google Scholar 

  55. 55.

    Regitz-Zagrosek V, Lehmkuhl E, Lehmkuhl HB, Hetzer R. Gender aspects in heart failure. Pathophysiology and medical therapy. Arch Mal Coeur Vaiss. 2004;97:899–908.

    CAS  PubMed  Google Scholar 

  56. 56.

    Ghadri JR, Sarcon A, Jaguszewski M, Diekmann J, Bataiosu RD, Hellermann J, Csordas A, Baumann L, Schoni AA, Luscher TF, Templin C. Gender disparities in acute coronary syndrome: a closing gap in the short-term outcome. J Cardiovasc Med (Hagerstown). 2015;16:355–62.

    Article  Google Scholar 

  57. 57.

    Lopez-Sendon J. To BNP or not to BNP. Eur Heart J. 2013;34:2498–500.

    Article  PubMed  Google Scholar 

  58. 58.

    Naesgaard PA, Leon de la Fuente RA, Nilsen ST, Woie L, Aarsland T, Staines H, Nilsen DW. Vitamin d predicts all-cause and cardiac mortality in females with suspected acute coronary syndrome: a comparison with brain natriuretic peptide and high-sensitivity C-reactive protein. Cardiol Res Pract. 2013;2013:398034.

    Article  PubMed  PubMed Central  Google Scholar 

  59. 59.

    McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

    CAS  Article  PubMed  Google Scholar 

  60. 60.

    Health UNIo. Angiogenesis in women with angina pectoris who are not candidates for revascularization (AWARE) Accessed 4 June 2017.

  61. 61.

    Zenovich AG, Panoskaltsis-Mortari A, Caron GJ, Kolb AG, Fremming R, Nelson WD, Taylor DA. Sex-based differences in vascular repair with bone marrow cell therapy: relevance of regulatory and Th2-type cytokines. Transplant Proc. 2008;40:641–3.

    CAS  Article  PubMed  Google Scholar 

  62. 62.

    Nelson WD, Zenovich AG, Ott HC, Stolen C, Caron GJ, Panoskaltsis-Mortari A, Barnes SA 3rd, Xin X, Taylor DA. Sex-dependent attenuation of plaque growth after treatment with bone marrow mononuclear cells. Circ Res. 2007;101:1319–27.

    CAS  Article  PubMed  Google Scholar 

  63. 63.

    Januzzi JL Jr, Lyass A, Liu Y, Gaggin H, Trebnick A, Maisel AS, D'Agostino RB Sr, Wang TJ, Massaro J, Vasan RS. Circulating proneurotensin concentrations and cardiovascular disease events in the community: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2016;36:1692–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Fawad A, Schultz C, Nilsson PM, Orho-Melander M, Melander O. 1C.07: proneurotensin independently predicts cardiovascular disease. The Malmo preventive project. J Hypertens. 2015;33(Suppl 1):e11.

    Article  Google Scholar 

  65. 65.

    Melander O, Maisel AS, Almgren P, Manjer J, Belting M, Hedblad B, Engstrom G, Kilger U, Nilsson P, Bergmann A, Orho-Melander M. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA. 2012;308:1469–75.

    CAS  Article  PubMed  Google Scholar 

  66. 66.

    Hu FB, Stampfer MJ, Manson JE, Grodstein F, Colditz GA, Speizer FE, Willett WC. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med. 2000;343:530–7.

    CAS  Article  PubMed  Google Scholar 

  67. 67.

    MC K. Basics of biomarkers American College Cardiology. Accessed 4 June 2017.

Download references


This study received funding from the Women’s Guild of Cedars-Sinai Medical Center, Los Angeles, CA, The Ladies Hospital Aid Society of Western Pennsylvania, Pittsburgh, PA, and QMED, Inc., Laurence Harbor, NJ, the Edythe L. Broad Women’s Heart Research Fellowship, the Barbra Streisand Women’s Cardiovascular Research and Education Program, the Linda Joy Pollin Women’s Heart Health Program, the Erika J. Glazer Women’s Heart Research Initiative, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, CA.

Author information




All authors contributed to the drafting, editing, and approval of the final manuscript.

Corresponding author

Correspondence to C. Noel Bairey Merz.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sobhani, K., Nieves Castro, D.K., Fu, Q. et al. Sex differences in ischemic heart disease and heart failure biomarkers. Biol Sex Differ 9, 43 (2018).

Download citation


  • Sex
  • Cardiovascular
  • Biomarker